<DOC>
	<DOC>NCT00690768</DOC>
	<brief_summary>The purpose of this study is to compare the amount of intraoperative intraocular bleeding during 23-gauge pars plana vitrectomy (PPV) for diabetic traction retinal detachment (TRD) with and without preoperative intravitreal bevacizumab treatment.</brief_summary>
	<brief_title>Pars Plana Vitrectomy (PPV) Versus Preoperative Intravitreal Bevacizumab Plus PPV to Treat Diabetic Tractional Retinal Detachment (IBETRA)</brief_title>
	<detailed_description />
	<mesh_term>Retinal Diseases</mesh_term>
	<mesh_term>Diabetic Retinopathy</mesh_term>
	<mesh_term>Retinal Detachment</mesh_term>
	<mesh_term>Dissociative Disorders</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Temazepam</mesh_term>
	<criteria>Macular traction retinal detachment lasting three months or less secondary to diabetic retinopathy. Massive vitreous hemorrhage preventing from detailed posterior pole examination; Previous intraocular surgery other than cataract surgery Hemodialysis, known bleeding disorders or use of anticoagulants drugs other than aspirin Prothrombin time, partial thromboplastin time or platelet count without normal limits History of previous thromboembolic events</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2008</verification_date>
	<keyword>Diabetic Retinopathy</keyword>
	<keyword>Retinal detachment</keyword>
	<keyword>Vitreous Hemorrhage</keyword>
	<keyword>Bevacizumab</keyword>
	<keyword>preoperative</keyword>
	<keyword>pars plana vitrectomy</keyword>
</DOC>